Sirakoss Receives CE Mark For Osteo3 Synthetic Bone Graft Substitute
In All, PortfolioRepresents New Hope for Repairing Challenging Bone Fractures Aberdeen, UK, January 31, 2019– SIRAKOSS Ltd, a developer of nanosynthetic bone graft substitutes to transform the treatment of spinal fusions and bone defects, announced today it has been granted CE Mark clearance in the European Union…